From: Disease burden in patients with acute hepatic porphyria: experience from the phase 3 ENVISION study
Characteristic | Placebo (n = 46) | Givosiran (n = 48) | Total (N = 94) |
---|---|---|---|
Prior chronic symptoms, n (%) | 26 (57) | 23 (48) | 49 (52) |
Prior chronic opioid use, n (%) | 13 (28) | 14 (29) | 27 (29) |
Nausea symptoms (medical history), n (%) | 10 (22) | 7 (15) | 17 (18) |
Fatigue (medical history), n (%) | 4 (9) | 1 (2) | 5 (5) |
Daily worst nausea score, weekly mean (SD) | 1.9 (1.8) | 1.6 (1.7) | 1.7 (1.8) |
Daily worst fatigue score, weekly mean (SD) | 4.7 (2.3) | 4.1 (2.6) | 4.4 (2.5) |
Daily worst pain score, weekly mean (SD) | 3.7 (2.2) | 3.0 (2.3) | 3.3 (2.3) |
Bodily pain domain score (SF-12), mean (SD) | 34.4 (9.0) | 37.6 (9.9) | 36.0 (9.6) |